Notably, we demonstrated that treatment with rIL-12 overcomes B-ALL-induced immunosuppression, highlighted by the establishment of an immunostimulatory leukemia microenvironment in the bone marrow, characterized by high levels of IFN-γ, IL-2, and various chemokines, higher numbers activated DC subsets in the bone marrow, and elevated numbers of highly functional CD8+ T-cells. This evidence concerns the gene IL2 and precursor B-cell acute lymphoblastic leukemia.